Astellas Pharma Inc. 4503
TSE · Japan · Health Technology
¥2,310.50-10.00 (-0.43%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
This article first appeared on GuruFocus. Astellas Pharma Inc (ALPMF) recently announced a total dividend of $0.25 per share, with the ex-dividend date set for 2026-09-29. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.
Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the appointment of Glenn Sblendorio, M.B.A., as Chairman of its Board of Directors. Mr. Sblendorio is a seasoned biotechnology executive and board member with more than three decades of experience leading corporate strategy, finance, business development and capital markets initiatives. Most recently, he was Chief Executive Officer of IVERIC bio, Inc. (acquired by
Astellas Pharma shares have quietly built a strong track record, which raises a simple question for anyone looking at the stock today. Are the current cash flows of Astellas Pharma, and what investors expect them to deliver over time, enough to justify where the share price now sits? Over the past 5 years the stock has returned 54.9%, which puts real weight on whether the current price still lines up with the cash being generated by the business. The company relies heavily on its portfolio...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.